Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

Published:2021-09 Issue:9 Volume:24 Page:1302-1307
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

King-Kallimanis Bellinda L.,Lederer Nirosha Mahendraratnam,Kim Janice,Nair Abhilasha,Horodniceanu Erica,Bhatnagar Vishal,Kluetz Paul G.

Funder

U.S. Food and Drug Administration

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference21 articles.

1. 21st Century Cures Act. H.R. 114th US Congress (2015).

2. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials;Di Maio;J Clin Oncol,2015

3. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment;Basch;JAMA,2017

4. The imperative for a new approach to toxicity analysis in oncology clinical trials;Thanarajasingam;J Natl Cancer Inst,2015

5. Reporting of HRQoL results from the PALOMA-2 trial: relevant data are still missing;Kaiser;Ann Oncol,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations to address respondent burden associated with patient-reported outcome assessment;Nature Medicine;2024-02-29

2. Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials;Value in Health;2023-10

3. Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection;Nature Communications;2022-10-12

4. Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer;Translational Oncology;2022-06

5. Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials;The Lancet Oncology;2022-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3